1. Home
  2. EVRG vs UTHR Comparison

EVRG vs UTHR Comparison

Compare EVRG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evergy Inc.

EVRG

Evergy Inc.

N/A

Current Price

$81.15

Market Cap

20.0B

Sector

Utilities

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$550.34

Market Cap

23.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVRG
UTHR
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.0B
23.1B
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
EVRG
UTHR
Price
$81.15
$550.34
Analyst Decision
Buy
Buy
Analyst Count
13
15
Target Price
$91.36
★ $651.86
AVG Volume (30 Days)
★ 2.0M
650.3K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
★ 3.45%
N/A
EPS Growth
N/A
★ 13.07
EPS
0.64
★ 13.07
Revenue
★ $5,961,600,000.00
$1,483,300,000.00
Revenue This Year
$5.46
N/A
Revenue Next Year
$5.83
$12.09
P/E Ratio
$125.81
★ $40.76
Revenue Growth
1.95
★ 2.38
52 Week Low
$71.41
$409.15
52 Week High
$88.62
$609.35

Technical Indicators

Market Signals
Indicator
EVRG
UTHR
Relative Strength Index (RSI) 57.78 60.62
Support Level $80.05 $526.30
Resistance Level $83.90 $580.88
Average True Range (ATR) 1.03 20.47
MACD 0.39 5.42
Stochastic Oscillator 100.00 70.26

Price Performance

Historical Comparison
EVRG
UTHR

About EVRG Evergy Inc.

Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission. The utility has a combined rate base of more than $20 billion, about half in Kansas and the rest split between Missouri and interstate transmission. Evergy is one of the largest wind energy suppliers in the US.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: